

Hospital Outcomes and Cost for Patients Undergoing a Customized Individually Made TKA vs Off-The-Shelf TKA.

Gregory Martin, MD; Alyssa Swearingen; Steven Culler, PhD

Summary of the presentation from ICJR Pan-Pacific 2014, Abstract #O18A3

Introduction

Despite excellent survivorship, published literature suggests that on average, 15-39% of patients are dissatisfied with the result of their TKA.^{1,2} Newer technologies may improve the value of care delivered to TKA patients by providing better clinical outcomes at similar or lower total cost of care. The purpose of this study was to compare a variety of the hospital outcomes between patients undergoing TKA using either a Customized Individually Made (CIM) TKA (ConforMIS iTotal) or a Standard Off-the-Shelf (OTS) TKA.

Methods

A retrospective review was conducted for consecutive TKA patients treated in a single institution, by the same surgeon, between March 2010 and November 2013. The study sample consisted of 248 TKA hospitalizations having received either CIM TKA (126) or OTS TKA (122). A subset of 19 hospitalizations in the CIM arm and 30 hospitalizations in the OTS arm were for bilateral procedures. Data collected included: patient demographics, length of procedure metrics, length of hospital stay, blood transfusion rates, patient discharge disposition, adverse event rates at discharge and total hospital cost. Hospital costs were calculated from billed charges and were adjusted into 2013 US Dollars by using the appropriate annual value for the hospital specific cost/charge index for all hospitalizations under DRG 470. Uni-variate differences in selected outcome measures between the two study arms were assessed with Chi-square analysis or Fisher's exact test for discrete variables and Student's t test for continuous variables. A p-value of ≤ 0.05 was considered statistically significant in this study.

Results

There were no statistical differences in the demographics (age, sex, BMI) between the two arms. The CIM implant showed significantly lower transfusion rates (2.4% vs 10.7%; $p=0.009$). The adverse event rate at discharge was significantly lower in the CIM arm than the OTS arm (1.6% vs 13.9%; $p<0.001$). Differences in length of stay reached borderline significance (CIM 3.0 vs OTS 3.2; $p=0.057$), with a significantly larger number of patients in the CIM group being discharged in <3 days ($p=0.033$) (Figure 1). When discharge disposition was analyzed, it was seen that a significantly lower percentage of patients in the CIM group were discharged to acute care facilities (2.4% vs 13.9%; $p<0.001$). In addition, when comparing a subset of the data among patients receiving a simultaneous bilateral TKA, patients in the CIM group were more likely to be discharged to home or home with care when compared to the OTS group (58% vs 17%; $p<0.001$) (Figure 2). Finally after adjusting for inflation, the total hospital cost between the two groups was not statistically different (CIM \$16,192 vs OTS 16,240; $p=0.913$).




Figure 1: Comparison of key outcomes between OTS and ConforMIS TKAs for all hospitalizations. * indicates statistical significance.




Figure 2: Comparison of key outcomes between OTS and ConforMIS simultaneous bilateral TKAs. * indicates statistical significance.

Discussion

Risk adjusted odds-ratios indicate that patients in the OTS arm were 4 times more likely to experience a transfusion and 3.7 times more likely to have an adverse event than patients in the CIM arm. Patients treated with a CIM implant showed a trend towards a shorter length of stay and a better discharge disposition than patients in the OTS arm. Previous studies have reported an associated cost of \$2,200 per incident of blood transfusion along with a \$16,000 cost associated with discharge to acute care facilities.^{3,4} Therefore, the lower transfusion rates and better discharge disposition with the CIM TKA seems to provide a better value proposition for hospitals and insurers, when compared to OTS TKA. These improved outcomes for the CIM group were achieved without an increase in hospital costs. Future studies need to be conducted to examine the potential hospital savings associated with lower inventory management and sterilization cost savings with the single package CIM implant.

REFERENCES

1. Hawker, et al; Health-Related Quality of Life after Knee Replacement. Journal of Bone and Joint Surgery; 1998, 80-A #2: 163-173
2. Suda, et al; Are Patients' Expectations of Hip and Knee Arthroplasty Fulfilled? A Prospective Study of 130 Patients. Orthopedics; 2010, 33 #2: 76-80
3. Szubski, et al; National Trends in Utilization and Outcomes of Allogenic Blood Transfusion in Primary Total Knee Arthroplasty, 2000-2009. ISTA Annual Meeting 2013. Poster #2451
4. Nicholas L. Ramos, Emily L. Wang, Raj J. Karia, Lorraine H. Hutzler, Claudette M. Lajam, Joseph A. Bosco. (2014) Correlation Between Physician Specific Discharge Costs, LOS, and 30-day Readmission Rates: An Analysis of 1,831 cases. The Journal of Arthroplasty



ConforMIS, Inc.
28 Crosby Dr., Bedford, MA 01730
Phone: 781.345.9001 | Fax: 781.345.0147
www.conformis.com

Authorized Representative: Medical Device Safety Service, GMBH • Schiffgraben 41, 30175 Hannover, Germany
P: +49 (511) 6262.8630 • F: +49 (511) 6262.86333

CE
0086

Copyright © by ConforMIS, Inc. All rights reserved. iTotal and ConforMIS are registered trademarks of ConforMIS.

CAUTION: USA federal law restricts this device to sale by or on the order of a physician. The ConforMIS Cruciate Retaining Total Knee Replacement System (iTotal G2) is intended for use only by fully trained physicians. Prior to use of a ConforMIS device, please review the instructions for use and surgical technique for a complete listing of indications, contraindications, warnings, precautions, and directions for use.

MK-02956-AA 8/14